Bernadette Baldin

Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009–2013 French PharmacoVigilance assessment

Guillaume Moulis, Haleh Bagheri, L. Sailler et al. · European Journal of Internal Medicine · 2014 · 31 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Is anti-factor Xa chromogenic assay for Rivaroxaban appropriate in clinical practice? Advantages and comparative drawbacks

Guillaume Bardy, Florence Fischer, Anny Appert et al. · Thrombosis Research · 2015 · 20 citations

Medicine, Pharmacology, Pharmacotherapy +10

Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database

Layla Saliba, Guillaume Moulis, Malak Abou Taam et al. · Fundamental and Clinical Pharmacology · 2015 · 15 citations

Medicine, Oncology, Pharmacology +13

Are nilotinib‐associated vascular adverse events an under‐estimated problem?

Marie Stève‐Dumont, Bernadette Baldin, Laurence Legros et al. · Fundamental and Clinical Pharmacology · 2015 · 11 citations

Medicine, Pharmacology, Pharmacotherapy +10